[1]
|
Lee, E. and Kazerooni, E.A. (2022) Lung Cancer Screening. Seminars in Respiratory and Critical Care Medicine, 43, 839-850. https://doi.org/10.1055/s-0042-1757885
|
[2]
|
Oliver, A.L. (2022) Lung Cancer: Epidemiology and Screening. Surgical Clinics of North America, 102, 335-344.
https://doi.org/10.1016/j.suc.2021.12.001
|
[3]
|
Giroux, D.J., Rami-Porta, R., Chansky, K., et al. (2009) The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project. Journal of Thoracic Oncology, 4, 679-683. https://doi.org/10.1097/JTO.0b013e3181a52370
|
[4]
|
Kotecha, R., Langer, C., Ernani, V., et al. (2022) First-Line Tumor Treating Fields (Ttfields; 150 KHZ) Therapy plus Pembrolizumab for Advanced or Metastatic Intrathoracic Non-Small Cell Lung Cancer: The Phase 2 EF-36/Keynote B36 Pilot Study. Journal for Immunotherapy of Cancer, 10, A735. https://doi.org/10.1136/jitc-2022-SITC2022.0703
|
[5]
|
Ettinger, D.S., Wood, D.E., Aisner, D.L., et al. (2022) Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 497-530.
https://doi.org/10.6004/jnccn.2022.0025
|
[6]
|
Ettinger, D.S., Wood, D.E., Aisner, D.L., et al. (2021) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19, 254-266.
https://doi.org/10.6004/jnccn.2021.0013
|
[7]
|
Lococo, F., Torricelli, F., Rossi, G., et al. (2017) Inter-Relationship between PD-L1 Expression and Clinic-Pathological Features and Driver Gene Mutations in Pulmonary Sarcomatoid Car-cinomas. Lung Cancer, 113, 93-101.
https://doi.org/10.1016/j.lungcan.2017.09.009
|
[8]
|
Yadavilli, S., Waight, J.D., Brett, S., et al. (2023) Activating Inducible T-Cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Block-ade. Cancer Research Communications, 3, 1564-1579.
https://doi.org/10.1158/2767-9764.CRC-22-0293
|
[9]
|
Nishino, M., Ramaiya, N.H., Hatabu, H., et al. (2017) Monitoring Immune-Checkpoint Blockade: Response Evaluation and Biomarker Development. Nature Reviews Clinical Oncology, 14, 655-668.
https://doi.org/10.1038/nrclinonc.2017.88
|
[10]
|
Sobande, F., Samayoa, L.M., Moore, A.R., et al. (2011) Primary Pulmonary Synovial Sarcoma Presenting as a Breast Mass. The Breast Journal, 17, 418-419. https://doi.org/10.1111/j.1524-4741.2011.01094.x
|
[11]
|
Janssen, J.P., Mulder, J.J., Wagenaar, S.S., et al. (1994) Primary Sarcoma of the Lung: A Clinical Study with Long-Term Follow-Up. The Annals of Thoracic Surgery, 58, 1151-1155. https://doi.org/10.1016/0003-4975(94)90476-6
|
[12]
|
Zheng, Y., Fu, Y., Zhong, Q., et al. (2022) The Treatment of Advanced Pulmonary Sarcomatoid Carcinoma. Future Oncology, 18, 727-738. https://doi.org/10.2217/fon-2021-1071
|
[13]
|
Weissferdt, A. (2018) Pulmonary Sarcomatoid Carcinomas: A Review. Advances in Anatomic Pathology, 25, 304-313.
https://doi.org/10.1097/PAP.0000000000000202
|
[14]
|
Gong, C., Xiong, H., Qin, K., et al. (2022) MET Alterations in Advanced Pulmonary Sarcomatoid Carcinoma. Frontiers in Oncology, 12, Article ID: 1017026. https://doi.org/10.3389/fonc.2022.1017026
|
[15]
|
Mok, T.S.K., Wu, Y.-L., Kudaba, I., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7
|
[16]
|
Herbst, R.S., Baas, P., Kim, D.-W., et al. (2016) Pembroli-zumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550.
https://doi.org/10.1016/S0140-6736(15)01281-7
|
[17]
|
Yang, J.-J., Huang, C., Fan, Y., et al. (2022) Camrelizumab in Different PD-L1 Expression Cohorts of Pre-Treated Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Study. Cancer Immunology, Immunotherapy, 71, 1393-1402. https://doi.org/10.1007/s00262-021-03091-3
|
[18]
|
Domblides, C., Leroy, K., Monnet, I., et al. (2020) Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. Journal of Thoracic Oncology, 15, 860-866. https://doi.org/10.1016/j.jtho.2020.01.014
|
[19]
|
Zhou, C., Chen, G., Huang, Y., et al. (2021) Camrelizumab plus Carboplatin and Pemetrexed versus Chemotherapy Alone in Chemotherapy-Naive Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (CameL): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Respiratory Medicine, 9, 305-314.
https://doi.org/10.1016/S2213-2600(20)30365-9
|
[20]
|
Qian, X., Wang, Y., Liu, F., et al. (2022) The Efficacy and Safety Analysis of First-Line Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma. Frontiers in Immu-nology, 13, Article ID: 956982.
https://doi.org/10.3389/fimmu.2022.956982
|